In-vitro flow assessment study of intra-saccular endovascular devices for brain aneurysm treatment: SEAL™ vs. WEB™ - Scorecard - MDSpire

In-vitro flow assessment study of intra-saccular endovascular devices for brain aneurysm treatment: SEAL™ vs. WEB™

  • By

  • Hamid Mansouri

  • Nedim Gulkaya

  • Matthew J. Gounis

  • Mohammad AlMajali

  • Amit Chaudhari

  • Darwin G. Ramirez Abreu

  • Syed F. Zaidi

  • Yazan K. Ashouri

  • Naoki Kaneko

  • Brian T. Jankowitz

  • David J. Altschul

  • Boris Pabon

  • Pervinder Bhogal

  • Thomas J. Wolfe

  • Edgard L. Pereira

  • Aamir Badruddin

  • Laila Ibrahim

  • Omid Amili

  • Osama O. Zaidat

  • June 19, 2026

  • 0 min

Share

Clinical Scorecard: In Vitro Evaluation of Flow Dynamics in Intra-Saccular Endovascular Devices for Treating Brain Aneurysms: A Comparison of SEAL™ and WEB™

At a Glance

CategoryDetail
ConditionBrain Aneurysms
Key MechanismsIntrasaccular devices disrupt aneurysmal flow dynamics.
Target PopulationPatients with wide-neck bifurcation aneurysms.
Care SettingNeurointerventional procedures.

Key Highlights

  • SEAL devices showed greater residence time compared to WEB-SL.
  • Velocity magnitude significantly decreased with SEAL devices.
  • Particle image velocimetry (PIV) method effectively characterized flow dynamics.

Guideline-Based Recommendations

Diagnosis

  • Utilize digital subtraction angiography (DSA) for aneurysm confirmation.

Management

  • Consider SEAL devices for improved flow disruption in WNBA.

Monitoring & Follow-up

  • Assess flow dynamics using PIV in controlled settings.

Risks

  • Potential complications from device deployment in complex aneurysm configurations.

Patient & Prescribing Data

Individuals with wide-neck bifurcation aneurysms.

SEAL devices may enhance occlusion rates compared to WEB-SL.

Clinical Best Practices

  • Employ in vitro flow experiments to evaluate device performance.
  • Use appropriate models to simulate physiological conditions.

Related Resources & Content

Original Source(s)

In-vitro flow assessment study of intra-saccular endovascular devices for brain aneurysm treatment: SEAL™ vs. WEB™

  • by Hamid Mansouri, Nedim Gulkaya, Matthew J. Gounis, Mohammad AlMajali, Amit Chaudhari, Darwin G. Ramirez Abreu, Syed F. Zaidi, Yazan K. Ashouri, Naoki Kaneko, Brian T. Jankowitz, David J. Altschul, Boris Pabon, Pervinder Bhogal, Thomas J. Wolfe, Edgard L. Pereira, Aamir Badruddin, Laila Ibrahim, Omid Amili, Osama O. Zaidat

  • June 19, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Case report: Emergency management of adjacent arterial injury during inferior vena cava angioplasty in a patient with Budd-Chiari syndrome